Everence Capital Management’s PTC Therapeutics PTCT Stock Holding History

Everence Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$232K	Buy	+2,849	New	+$206K	0.01%	762

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Everence Capital Management's PTCT Position: Q2 2026 in Review

Everence Capital Management opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 2,849 shares worth $232K. The stake represents 0.01% of the portfolio and ranks #762 among its holdings.

382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Everence Capital Management held 2,849 shares of PTC Therapeutics worth $232K as of Q2 2026.
PTC Therapeutics was a new Everence Capital Management position in Q2 2026.
PTC Therapeutics made up 0.01% of Everence Capital Management's portfolio in Q2 2026, its #762 holding.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.